Cell Origins Partners with RayzeBio to Develop Targeted Radiopharmaceuticals
Columbia, MO, October 13, 2022
This partnership will combine Cell Origins' expertise in phage display and peptide ligand discovery with RayzeBio's experience in radiopharmaceuticals. “We are looking forward to working with RayzeBio because of their innovative and strategic presence in the radiopharmaceutical space.” said Mette Soendergaard, CSO of Cell Origins. “Also, as a women-owned company, we appreciate that RayzeBio has promoted women to all levels of leadership in their company.”
Phage display is a powerful tool for drug discovery. It is a technique in which a phage (a virus that infects bacteria) is used to display a polypeptide of interest on its surface such as an antibody, peptide, nanobody, or other protein-based molecules. The displayed polypeptide can then be selected for its ability to bind to a specific target, such as a biomarker. During selection experiments, the phages are incubated with the target molecule and bound phages are collected. The displayed polypeptides can then be identified by DNA sequencing.
Radiopharmaceuticals that are targeted to a specific organ or tissue can offer advantages over traditional radiotherapy. By increasing the radiation dose to the tumor and minimizing exposure of healthy tissues, these treatments can improve patient outcomes. While there is still some research to be done in order to optimize targeting and minimize side effects, the potential benefits of using targeted radiopharmaceuticals make them an exciting area of development in oncology.
“We specialize in tricky targets, finding ligands that are challenging to discover using computational
methods or by more traditional phage selection processes.”
Mette Soendergaard, CSO of Cell Origins
“We specialize in tricky targets, finding ligands that are challenging to discover using computational methods or a more traditional phage selection processes.” Stated Dr. Soendergaard of Cell Origins. With the ever-growing need for new cancer treatments, this partnership will hopefully lead to some very important breakthroughs.
Cell Origins is a phage display company that came out of the birthplace of phage display, Columbia, MO. Cell Origins is uniquely specialized in combining multiple tiers of selection strategies as well as proprietary methods to identify peptides with exceptional drug properties. The scientists at Cell Origins also have an interest in developing phage products to meet critical laboratory needs and are developing a product for identification and phenotypic characterization of cell lines.